In the August 14 Proceedings of the National Academy of Sciences, Yee Cho and colleagues at the National Institutes of Health, Bethesda, MD, report the use of DNA microarrays to resolve aspects of the ...

Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...

Antisense oligonucleotide (ASO) technology has accelerated drug discovery in the last few decades with several ASO-based ...

Among the DNA repair genes identified ... These neurons were then treated with an antisense oligonucleotide (ASO) that binds to MSH3 mRNA, reducing its expression, and changes in CAG repeat ...

Scientists use short oligonucleotides as primers for polymerase chain reaction and next-generation sequencing, in DNA microarrays and fluorescence in situ hybridization, and in antisense therapies. (1 ...

ASOs, or antisense oligonucleotides, are short, synthetic sequences of single-stranded DNA that alter RNA expression or splicing in the process of translation, where genetic code (DNA) is used to ...

The DNA repair protein MSH3 promotes the growth of CAG expansions in neurons. Knocking it down with an antisense oligonucleotide blocked CAG expansion in HD neurons. The ASO also took down MSH3 in the ...

As surprisingly high proportions of eukaryotic genomes are transcribed, with numerous noncoding and antisense RNAs being ... from evolutionarily unrelated DNA is noise, so analysis of cells ...

sequences (as DNA) into the target sequence (see Fig. 2 for guidance). Insert the miR-30 loop sequence between the sense and the antisense sequences and add the appropriate flanking sequences of ...

These informational drugs, known as antisense therapies, chemically modify genetic sequences to reach specific targets and block disease-associated mRNA. Agrawal likens these therapies to “genetic ...